Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-TOLE-HAIC-ICC: Neoadjuvant toripalimab + lenvatinib + HAIC in resectable high‑risk intrahepatic cholangiocarcinoma
ChiCTR2600125895Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: 1-year event-free survival (1-year EFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
toripalimablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2600125895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125895.